Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

New DGAT-2 inhibitors discovered at Inorbit Therapeutics

Sep. 7, 2021

MKK-4 inhibition for liver regeneration

Aug. 27, 2021

Hepagene reports phase I data on FXR agonist HPG-1860

Aug. 24, 2021

Phase IIb study of izencitinib in ulcerative colitis misses primary endpoint

Aug. 24, 2021

Phase II topline data show efficacy of MS-1819 plus PERT in severe exocrine pancreatic insufficiency

Aug. 19, 2021

Preclinical toxicology study supports development of antidiarrheal lechlemer

Aug. 18, 2021

Inhibitors of TNF-alpha- and IL-6-induced adhesion show activity in IBD models

Aug. 17, 2021

HepaRegeniX initiates first-in-human trial of HRX-0215

Aug. 12, 2021

Positive topline data from phase Ia/Ib trial of CB-4211

Aug. 11, 2021

Heparegenix identifies new MAPKK 4 inhibitors

Aug. 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...